Home > Haematology > ASH 2019 > Venous Thromboembolism > Rivaroxaban is safe and effective for paediatric venous thromboembolism

Rivaroxaban is safe and effective for paediatric venous thromboembolism

Presented By
Prof. Guy Young, Children's Hospital Los Angeles, USA
Conference
ASH 2019
Trial
Phase 3, EINSTEIN-Jr
New data from the randomised phase 3 EINSTEIN-Jr study support the use of rivaroxaban, either as tablet or in liquid suspension, for children with venous thromboembolism (VTE), using an age- and weight-adjusted algorithm. These data will likely form the basis for an official indication in the near future. VTE among paediatric patients differs substantially from adults in many aspects, including aetiology, anatomical location, frequency, and recovery. This different natural history of VTE in children, coupled with metabolic variation based on age and body weight, complicate the anticoagulant options available in daily practice. No formulations of direct oral anticoagulants —either liquid (for small children) or tablet— are currently available for children with VTE; this unmet need drove the current study. Prof. Guy Young (Children's Hospital Los Angeles, USA)...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on